Tango is now a focused PRMT5 bet
- Tango has narrowed around its PRMT5 cancer-drug franchise after shutting down TNG260 and halting TNG961 development.
- The lead drug, vopimetostat, showed 25% ORR and 7.2 months median progression-free survival in second-line MTAP-deleted pancreatic cancer.
- The company had $379.8 million in cash, cash equivalents, and marketable securities at March 31, 2026, with runway into 2028.
- Tango is still pre-revenue from product sales, so investors are funding trial progress rather than a proven commercial business.
- A sole API supplier tied to WuXi AppTec is a key watch item because proposed U.S. limits could disrupt clinical trial supply.
A cleaner but narrower pipeline
Tango is now much easier to understand. The company has moved away from TNG260, a CoREST inhibitor, after the trial showed limited clinical benefit. It also has no current plan to advance TNG961. That leaves the story centered on PRMT5, mainly vopimetostat and TNG456.
The bull case is that this focus helps. Vopimetostat has the best data in the portfolio so far. In second-line MTAP-deleted pancreatic cancer, the Phase 1/2 data showed 25% ORR, or objective response rate, and 7.2 months median progression-free survival, which means the middle patient went that long before the cancer got worse. Tango also says its cash can fund work into 2028, so the company should not need to raise money right away just to reach the next data points.
The bear case is also clearer. Tango lost one of its bigger side bets when it chose to shut down TNG260. If PRMT5 data disappoints, there are fewer other clinical assets to support the stock. The company also depends on a sole API supplier affiliated with WuXi AppTec, which adds a supply-chain and political risk that has little to do with whether the science works.
The next year should answer basic questions. Investors need the vopimetostat registration path, safety and activity from RAS inhibitor combinations, the start of the Erasca ERAS-0015 study in the second half of 2026, and first TNG456 data in glioblastoma, a hard-to-treat brain cancer.
No drug sales yet
Tango does not yet sell an approved drug. Its work is research and clinical development. The long-term goal is to win approval for targeted cancer medicines and then earn product revenue, but that is still several steps away.
Today, cash comes from financings and the Gilead collaboration. In August 2025, Tango and Gilead ended the research term early, with no future research obligations for Tango. That led Tango to recognize the remaining deferred revenue, while future milestones and royalties stayed in place.
For the nine months ended September 30, 2025, Tango recognized $62.4 million of collaboration revenue, including a one-time $53.8 million amount in Q3 2025 tied to the end of the Gilead research term. That makes the reported revenue lumpy. It should not be read like normal drug sales.
The model breaks if trials fail, take too long, or need more money than planned. Biotech value can move a lot on one data update, especially when the pipeline has become more concentrated.
The PRMT5 core
Vopimetostat, also called TNG462
This is the lead PRMT5 inhibitor for MTAP-deleted cancers. Tango plans a clinical data update and a path to registration in 2026.
Vopimetostat combinations
Tango is testing vopimetostat with Revolution Medicines' RAS inhibitors and plans a Phase 1/2 trial with Erasca's ERAS-0015 in the second half of 2026. These studies could widen the drug's use if safety and activity hold up.
TNG456
TNG456 is a next-generation, brain-penetrant PRMT5 inhibitor aimed at glioblastoma. The Phase 1/2 trial began treating patients in May 2025, with initial data expected in 2026.
TNG260
TNG260 was a first-in-class CoREST inhibitor, but Tango is shutting down the clinical trial after limited clinical benefit. It now matters mostly as a lesson on pipeline risk.
TNG961
TNG961 is a molecular glue development candidate targeting HBS1L. Tango has no current plans to advance it, which further concentrates the company around PRMT5.
One reported business
Tango reports one operating segment: discovery and development of precision cancer medicines. The mix shown here reflects revenue status, not separate reporting segments, because all recognized revenue to date has come from collaboration activity rather than product sales.
What could break the thesis
PRMT5 data misses
High impact · Medium oddsTango is now much more tied to one mechanism, PRMT5 inhibition. If vopimetostat or TNG456 show weak activity, hard-to-manage side effects, or a narrow patient pool, the investment case could shrink fast. The TNG260 shutdown makes this risk larger than before.
Pivotal trial path is weaker than hoped
High impact · Medium oddsThe 7.2 months median progression-free survival result in second-line MTAP-deleted pancreatic cancer is the main support for a registration plan. But early and mid-stage data do not guarantee approval. The design, control arm, endpoints, and patient selection will decide how convincing the next study can be.
WuXi-linked supply disruption
High impact · Medium oddsTango says its sole API supplier for drugs used in clinical trials is affiliated with WuXi AppTec. Proposed U.S. actions aimed at WuXi could limit business with that supplier. A delay in drug substance supply could slow trials even if patient demand and data are strong.
Combination safety limits use
Medium impact · Medium oddsCombination studies can expand a drug's market, but they can also add toxicity. Tango is studying vopimetostat with RAS inhibitors from Revolution Medicines and plans a study with Erasca's ERAS-0015. If side effects stack up, the combo path may be less valuable.
Cash lasts, but not forever
Medium impact · Low oddsTango had $379.8 million in cash, cash equivalents, and marketable securities at March 31, 2026, and guided runway into 2028. That is strong for a clinical-stage biotech, but pivotal trials can be costly. A poor stock price or higher spending could make the next financing more painful.
In one breath
Does Tango Therapeutics have an approved drug?
No. Tango is pre-revenue from product sales and is still running clinical trials. Its current revenue has come from collaboration activity, mainly the Gilead agreement.
What is Tango's lead drug?
The lead drug is vopimetostat, also called TNG462. It is a PRMT5 inhibitor being developed for cancers with MTAP deletion, with a registration path expected in 2026.
Why did Tango shut down TNG260?
Tango said TNG260 showed limited clinical benefit in patients. The company is deprioritizing that program to focus resources on its PRMT5 pipeline.
How long is Tango funded?
Tango said its $379.8 million in cash, cash equivalents, and marketable securities at March 31, 2026 should fund operating expenses and capital needs into 2028. That does not remove trial risk, but it lowers near-term financing pressure.